Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Muraglitazar

Study type

Interventional

Funder types

Industry

Identifiers

NCT00094991

CV168-026

Details and patient eligibility

About

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes;
Serum triglyceride concentration < or = 600 mg/dL;
Body mass index < or = 37 kg/m2

Exclusion criteria

Type 1 diabetes;
History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
Congestive heart failure (NYHA Class III and IV);
Uncontrolled hypertension;
Women of Child Bearing Potential
History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease